CClinicalTrials.gg
CompletedNCT03444428Updated Oct 1, 2021

The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease

An observational study in Motor Neurone Disease and Hypoxemia and/or Hypercapnia, sponsored by Guy's and St Thomas' NHS Foundation Trust. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13
Ages
18 Years to 80 Years
Sex
All
01

Study summary

  • Patients with Motor Neurone Disease (MND) admitted to Lane Fox Unit /Royal Brompton Hospital and/or reviewed in Lane Fox Unit /Royal Brompton Hospital clinics and/or outreach review will be approached for participation in the study
  • Physiological assessment and measurement of arterial stiffness will be performed in all patients at baseline and after the use of non invasive ventilation for 6 weeks.
  • MND patients not requiring mechanical ventilation will serve as controls since non invasive ventilation cannot be withheld from MND patients in type II respiratory failure.
  • Data will be analysed to look for differences between groups, relationships in baseline or change from baseline in respiratory physiological measures, inflammatory indices, breathlessness, and arterial stiffness.

    • Age, Height, Weight
    • History and Physical Examination
    • Evaluation of dysponea: mMRC, Borg Scale (Seated-Supine)
    • Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
    • Sleep Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
    • 24 hour blood pressure monitor
    • Carotid-femoral pulse wave velocity
    • Respiratory Muscle Strength - Maximal Inspiratory Pressure, Maximal Expiratory Pressure, and Sniff Nasal Inspiratory Pressure
    • Spirometry - FEV1 and FVC
    • Arterial Blood Gas
    • CRP and fibrinogen (clinically)
    • Breathe CO exhale
Read the detailed description

The stiffness of the arterial wall is highly relevant to cardiovascular disease. Large elastic arteries and smaller muscular conduit arteries become stiffer with ageing, a process that is accelerated in the presence of cardiovascular disease. Arterial stiffness increases also with various disease states, including hypertension, diabetes mellitus, obesity, smoking, hypercholesterolemia, and kidney disease. Numerous techniques have been developed to measure arterial stiffness, either in single vessels or in entire muscular arterial trees. These techniques have increasingly been shown to improve stratification of cardiovascular risk and risk reduction beyond that provided by conventional risk factors. Furthermore, large artery stiffness, measured via carotid-femoral pulse wave velocity, independently predicts the risk of cardiovascular events in both clinical and community-based cohorts.

Abnormalities in arterial stiffness have been noted in disorders characterized by hypoxia with or without hypercapnia. These abnormalities could be driven by the risk factors for those conditions (e.g. cigarette smoke, obesity). In COPD, all studies are consistent showing a significant increase in arterial stiffness compared with ex-smokers without airway obstruction and nonsmoker healthy control subjects. The severity of airway obstruction is consistently related to arterial stiffness in COPD. Furthermore, airflow limitation arising from cigarette smoking, but not airflow limitation in non-smokers, was associated with arterial stiffness in a general population independently of established risk factors. The presence of OSA was associated with higher arterial stiffness indices independent of major confounders. In this context, OSA is associated with increased arterial stiffness independent of blood pressure.

Non invasive ventilation has been shown to reduce arterial stiffness in obstructive sleep apnea. In particular, there are studies that have examined the impact of continuous positive airway pressure (CPAP) on arterial stiffness (measured with pulse wave velocity) in OSA patients. Other studies have examined changes in arterial stiffness (measured with other than pulse wave velocity method) after treatment of OSA with CPAP. Furthermore, to the best of our knowledge no investigation exists on the impact of non invasive bilevel positive airway pressure ventilation on arterial stiffness in neuromuscular disease.

The Lane Fox Unit, the UK's largest weaning, rehabilitation and home ventilation unit, is treating neuromuscular patients. In neuromuscular disease, especially in MND, confounding factors as obesity, cigarette smoke, hypertension, and diabetes mellitus can be excluded. This gives the opportunity to determine whether hypoxemia and/or hypercapnia alone cause arterial stiffness. Furthermore, in this pilot study it will be investigated whether non invasive ventilation has any effect on arterial stiffness in MND patients.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Motor Neurone Disease

Inclusion criteria

  • MND diagnosis
  • The ability to perform the respiratory function testing satisfactorily
  • Stable clinical and functional state for at least four weeks before testing
  • BMI 20-30 kg•m-2

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Aged \<18, >80
  • Significant physical or psychiatric comorbidity that would prevent compliance with trial protocol
  • Unstable clinical state
  • Use of mechanical ventilation
  • Cardiovascular disorders (history, physical examination)
  • Known lung disease, such as asthma or COPD or any other cause of hypoxemia and/or hypercapnia but MND (history, physical examination, CXR review [High Resolution Computed Tomography if CXR is not compatible with neuromuscular disease alone])
  • Airway obstruction (FEV1/FVC\<0.75)
  • Diabetes mellitus
  • Obesity (BMI>30 kg•m-2)
  • Smoking history (>10 pack∙years or active smoker)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13 participants (actual)
Patient registry
No

Groups and cohorts

  • Non Invasive Ventilation

    * Age, height, weight * History and Physical Examination * Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine) * Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) * Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5) * 24h Blood Pressure monitor * Spirometry - FEV1 and FVC * Respiratory muscle strength - MIP, MEP, and SNIP * Arterial Blood Gases * Carotid-femoral pulse wave velocity * Breath CO exhale

    Other: Non Invasive Ventilation

  • Without Non Invasive Ventilation

    Age, height, weight * History and Physical Examination * Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine) * Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) * Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5) * 24h Blood Pressure monitor * Spirometry - FEV1 and FVC * Respiratory muscle strength - MIP, MEP, and SNIP * Arterial Blood Gases * Carotid-femoral pulse wave velocity * Breath CO exhale

    Other: Without Non Invasive Ventilation

Interventions

  • OtherNon Invasive Ventilation

    Assessments for those participants who are being set up onto NIV

  • OtherWithout Non Invasive Ventilation

    Assessments for those participants who are not being set up onto NIV

05

What researchers measure

Primary outcomes

  1. Comparing the pulse wave velocity between MND patients with hypoxemia and/or hypercapnia to those MND Patients that do not have hypoxemia and/or hypercapnia

    Is there a difference in pulse wave velocity between patients with MND who have and those who do not have hypoxemia and/or hypercapnia

    Time frame: 6 weeks

Secondary outcomes

  1. Comparison of pulse wave velocity values in MND patients to normal values

    To clarify if there is an increased pulse wave velocity in MND patients and quantify whether patients are within predicted values or not against current evidenced literature

    Time frame: 6 weeks

  2. Comparison of pulse wave velocity pre-post non invasive ventilation in MND patients

    Does NIV change pulse wave velocity in MND patients

    Time frame: 6 weeks

06

Study locations

2 sites
  • Guys and St Thomas NHS Trust
    London, SE1 7EH, United Kingdom
  • Royal Brompton and Harefield NHS Trust
    London, SW3 6NP, United Kingdom
07

References and documents

Individual participant data

Plan to share: No — No individual participant data will be available

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03444428
Lead sponsor
Guy's and St Thomas' NHS Foundation Trust
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Feb 21, 2017
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Oct 1, 2021

Study contacts

Patrick Murphy
principal investigator · Guys and St Thomas NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion